Polylaminin is not yet a drug: specialists warn against 'hype' on social media
Experts caution that the biotechnological compound polylaminin, popularized for its potential in treating spinal cord injuries, is still unproven and should not be considered a cure.
Debate on polylaminin could clarify the boundaries of science
The discussion surrounding the Brazilian clinical research on polylaminin highlights both the potential benefits and limitations of the molecule, which may offer hope in treating severe spinal injuries.
Use of polylaminin is monitored in real time by society: 'Like a Big Brother', says researcher
Research on polylaminin, a substance being studied as a possible treatment for spinal cord injuries, is closely monitored by society, according to lead researcher Tatiana Sampaio.
Polylaminin is promising, but must overcome clinical trials
Polylaminin shows promise as a potential treatment for severe spinal injuries but faces significant challenges in clinical testing.
Polylaminin: How the studies were conducted, what are the results so far, and what does Anvisa say? Understand
A groundbreaking Brazilian study on polylaminin shows promising results in restoring movement after severe injuries, with a pivotal clinical study approved by Anvisa set to begin next month.
Don't treat polylaminin as if it were the national team
The article discusses the recent hype surrounding polylaminin, a substance believed to regenerate spinal cord injuries, and its political implications in Brazil.
Polylaminin researcher will receive a medal from the government of Espírito Santo
Tatiana Sampaio, a researcher from UFRJ, will be awarded the Jerônimo Monteiro medal by the Espírito Santo government for her work on polylaminin, a molecular treatment for spinal cord injuries.
Neurologists alert to lack of evidence on the action of poly-L-lysine in spinal cord injury
Brazilian neurologists warn about insufficient scientific evidence supporting the use of poly-L-lysine for treating spinal cord injuries in humans.
Lecture with Tatiana Sampaio at IFTM in Patrocínio Sold Out in 28 Minutes
A lecture featuring scientist Tatiana Sampaio at IFTM in Patrocínio sold out just 28 minutes after registration opened.
VIDEO: Reporter Flávia Cintra hugs biologist Tatiana Sampaio, researcher leading studies on polylaminin
Reporter Flávia Cintra shares an emotional moment with biologist Tatiana Sampaio during a segment on the substance polylaminin, which offers hope for those with spinal cord injuries, going viral on social media.
This is Fantastic: the advances in experimental treatments with polylaminin
The article discusses promising advancements in experimental treatments involving polylaminin, a placenta-derived protein that may restore movement in patients with severe spinal cord injuries.
VIDEO: João Gomes interrupts show in Sapucaí to honor scientist leading research on polylaminin
Singer João Gomes interrupted a performance to pay tribute to researcher Tatiana Sampaio, who is recognized for her work on polylaminin for treating acute spinal cord injuries.
Tatiana Sampaio at IFTM in Patrocínio: how to participate in the event with the scientist who developed a molecule that can reverse spinal injuries
Tatiana Sampaio will be speaking at the IFTM in Patrocínio on March 12, focusing on her research that could aid recovery from spinal injuries.
Claes Hultling: That's why we had a sex room at the Spinal Clinic
Claes Hultling, a 31-year-old anesthesiologist, reflects on his transformative experience as a patient after a life-changing injury and shares his innovative ideas for the treatment of spinal cord injuries.
Tatiana Sampaio, scientist who developed a molecule that can reverse spinal cord injuries, participates in event at IFTM in Patrocínio
Tatiana Sampaio, a leading researcher in spinal cord injury recovery, will participate in the 'Extraordinary Women' event at the IFTM in Patrocínio, Brazil.
Polylaminin: a molecule discovered in Brazil 'by chance' that became hope to reverse spinal cord injuries
Polylaminin, a modified version of the naturally occurring laminin protein, is being studied as a new potential treatment for spinal cord injury victims in Brazil, although it is still in early clinical trial phases.
Podcast: the Brazilian experimental drug that may be hope for spinal cord injuries
The podcast discusses polylaminin, an experimental drug showing promise in restoring movement for patients with spinal cord injuries, highlighted by the case of a Brazilian influencer who regained arm movement after treatment.